GENE ONLINE|News &
Opinion
Blog

2022-04-06| ChinaM&A

Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs

by Joy Lin
Share To

Shanghai-based Hasten Biopharmaceutic has announced that it has acquired five cardiovascular and metabolism drugs from Japan’s Takeda, with the intent of marketing them in China. The deal, worth $322 million, was struck back in 2020 when Takeda was busy shedding non-core assets following its $59 billion buyout of Ireland-based Shire. 

The five drugs in the deal include Ebrantil, a medicine for hypertension, Edarbi, Basen, Blopress and Actos. Sales of the drugs reached $109.5 million in 2019. Staff related to drug sales will be transferred to Hasten; Takeda will continue to produce and supply the products to Hasten. 

 

Related Article: Takeda Taps Code Biotherapeutics to Develop Non-Viral Gene Therapies in $2 Billion Biobucks Deal

 

Backed by CBC

 

Hasten’s history is fairly recent – the biopharma was founded in September 2020 and funded by CBC Group, a healthcare-focused investment firm, Hefei Industry Investment Group, and the Feidong County of the Chinese city of Hefei. 

“This acquisition helps us further our purpose of building a best-in-class primary care platform in Asia,” Wei Fu, CEO of CBC, said. “CBC has an excellent track record of building next-generation healthcare companies with our unique investor-operator strategy.” CBC will continue to develop its portfolio companies to bring treatments to chronic disease patients, said Fu.  

 

Shire Buy Proves to be a Tough Pill to Swallow 

 

Takeda has been restructuring its portfolio since buying Shire in 2019. Back then, the Japanese drug giant had laid out plans to narrow its specialty areas to gastroenterology, rare disease, oncology, neuroscience and plasma-derived therapies – and offload up to $10 billion worth of non-core products to other companies. 

So far, the Shire acquisition has been a tough pill for Takeda to swallow. The drugmaker recently let go of an asset it had trumpeted as one of the jewels of the Shire takeover to a fresh rare disease company called Oak Hill Bio. That candidate – a recombinant insulin-like growth factor -1 (IGF-1) called OHB-607 – had reached Phase 2 studies and was indicated to treat complications of premature births. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
America’s Ongoing Battle For Lower Insulin Prices
2022-06-23
Quion Licenses Two Rare Skin Disease Candidates to Hong Kong WinHealth
2022-06-16
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top